Rose Shea
Psychiatric/Mental Health · New Haven, CTNPI 1801511217
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 307 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 29.4% of the total. 2025 is the largest year on record at $4,616, 4.9 times the $946 reported in 2023. Among psychiatric/mental health clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 307 payments — averaging $27.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- AbbVie$1K
- Alkermes, Inc.$917
- E.r. Squibb & Sons, L.L.C.$769
- Teva Pharmaceuticals USA, Inc.$714
- Otsuka America Pharmaceutical, Inc.$695
- plus $2K from 9 others
What the payments were for
- Food & beverage$8,26597%
- Education$2843%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 78 | $2,511 |
| AbbVie | 60 | $1,374 |
| Alkermes, Inc. | 30 | $917 |
| E.r. Squibb & Sons, L.L.C. | 46 | $769 |
| Teva Pharmaceuticals USA, Inc. | 15 | $714 |
| Otsuka America Pharmaceutical, Inc. | 20 | $695 |
| Neurocrine Biosciences, Inc. | 21 | $639 |
| Axsome Therapeutics, Inc. | 3 | $260 |
| Vanda Pharmaceuticals Inc. | 17 | $245 |
| Lundbeck LLC | 5 | $133 |
| Johnson & Johnson | 3 | $85 |
| Indivior Inc. | 3 | $68 |
| Gilead | 2 | $60 |
| Corium, LLC | 3 | $53 |
| USWM, LLC | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$987
- CAPLYTA$841
- VRAYLAR$625
- COBENFY$349
- Auvelity$250
- UZEDY$231
- REXULTI$125
- Austedo XR$125
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
How this compares
$8,549 in reported general payments places this provider in the 95th percentile of 679 psychiatric/mental health providers in Connecticut.
See all psychiatric/mental health providers in Connecticut →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $101,741 |
| VraylarCariprazine Hcl | 43 | $71,762 |
| Quetiapine Fumarate | 59 | $404 |
| Hydroxyzine Pamoate | 40 | $373 |
| Mirtazapine | 27 | $326 |
| Prazosin Hcl | 27 | $325 |
| Aripiprazole | 18 | $304 |
| Duloxetine Hcl | 20 | $279 |
| Hydroxyzine Hcl | 12 | $233 |
| Gabapentin | 32 | $221 |
| Clonidine Hcl | 27 | $158 |
| Escitalopram Oxalate | 14 | $134 |
| Propranolol Hcl | 11 | $103 |
| Trazodone Hcl | 20 | $101 |
| Buspirone Hcl | 24 | $91 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $639 | $101,74113 claims |
| AbbVieVraylar | $1,374 | $71,76243 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 679 psychiatric/mental health providers in Connecticut.
Other psychiatric/mental health in New Haven
- Max Greger-MoserNew Haven$15K
- Maurice BunnellNew Haven$4K
- Cristina MeehanNew Britain$224K
- Samantha MrazBridgeport$87K
- Philip FrickManchester$31K
- Gia SantoroWest Haven$25K
- Donna DraperDanbury$19K
- Zahida SairitupaDanbury$19K
- Hui HuNorwich$19K
- Patrick GagnonMilford$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.